Search

Displaying results 4791 - 4800 of 10000 in total
  1. Drug

    EGS21

    go.drugbank.com/drugs/DB05056
    Experimental

    It is a potential therapeutic for treating immune mediated disorders. … GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate

  2. Drug

    Annamycin

    go.drugbank.com/drugs/DB06420
    Investigational

  3. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    It is a new formulation that is based on the vertigo medication, Betahistine. … Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.

  4. Drug

    Tenoxicam

    go.drugbank.com/drugs/DB00469
    ApprovedInvestigational

    Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.

    Products: TENOXICAM 20 MG, ANALCAM TABLET 20 mg
  5. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  6. Drug

    4'-Methylene-5,8,10-trideazaaminopterin

    go.drugbank.com/drugs/DB05616
    Investigational

    It has been investigated for the treatment of Rheumatoid Arthritis (phase II). … CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier

  7. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  8. Drug

    Nisoxetine

    go.drugbank.com/drugs/DB09186
    Experimental

    It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI. … Nisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s.

  9. Drug

    L-cysteic acid

    go.drugbank.com/drugs/DB03661
    Experimental

    It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather. … It is an amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate.

  10. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.